MSCI vs STRO · P/E 37, rev $2.86B vs rev $62.0M
MSCI Inc (MSCI) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
MSCI Inc (MSCI) is a financial data & stock exchanges company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported MSCI revenue for 2024-12-31 was $2.86B. Net income was $1.11B. Revenue was up 12.9% from 2023-12-31 to 2024-12-31. MSCI currently screens at market cap $46.82B and trailing P/E 36.8.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
MSCI currently screens at market cap $46.82B and trailing P/E 36.8. STRO currently screens at market cap $470.8M.
Not investment advice. Open the MSCI and STRO stock pages for the full models.
Not investment advice.